EGFR and lung adenocarcinoma: Our findings offer novel evidence that EGFR-mutant tumors have a higher infiltration of Tregs compared with wild-type tumors, which could be the main cause of impaired response to PD-1 pathway blockade in EGFR-driven lung adenocarcinoma.